Accessibility StatementSkip Navigation INDIANAPOLIS, Oct. 16, 2025 /PRNewswire/ --Â Elanco Animal Health, Inc. (NYSE: ELAN) will host an Investor Day on Tuesday, December 9, 2025, from approximately 9 a.m. to 12 p.m. Eastern Time in New York City. The event will feature presentations from Elanco's senior leadership team on the company's strategic priorities, financial outlook, and innovation pipeline – defining Elanco's new era of growth. Advance registration for the in-person event is required; institution ...

Core Insights - The company reported a consolidated revenue of €1,102.4 million for the first half of 2025, reflecting a growth of +5.8% overall and +9.2% at constant exchange rates [1][6] - The growth in revenue is driven by the companion animal segment, which increased by +11.3%, and the farm animal segment, which grew by +6.1% [1][9] - The company has upgraded its full-year revenue guidance, now expecting growth between 5.5% and 7.5% at constant rates and scope [4][10] Revenue Performance - The third-quarter consolidated revenue reached €364.1 million, showing a strong growth of +12.5% at constant exchange rates and scope compared to the same period in 2024 [3] - Revenue growth in Europe was +6.1%, primarily driven by the companion animal segment, which grew by +9.2% [3][7] - North America experienced exceptional growth of +48.5% at constant exchange rates, largely due to a restocking effect on dental products [3][8] Regional Analysis - Latin America recorded strong growth of +11.1%, supported by both companion animals (+14.2%) and farm animals (+17.0%) [3][8] - The IMEA zone (India, Middle East, and Africa) showed sustained growth of +9.7%, predominantly in the farm animal segment [3][5] - East Asia experienced growth of +6.2%, driven by Japan, while China faced a decline of -2.6% due to challenges in the farm animal segment [5][8] Product Segment Performance - The companion animal business grew by +11.3%, driven by strong sales in dental, dermatology, petfood, and specialty products [9] - The farm animal segment showed growth of +6.1%, mainly from the ruminant segment with vaccines and nutritional products [9] - The integration of the acquired company Sasaeah contributed +1.4 percentage points to overall growth [6][10] Financial Outlook - The adjusted recurring operating income is expected to be around 16% for the year [4][10] - The company anticipates a moderate impact from potential increases in customs tariffs in the United States, with an estimated direct impact of around US$4 million for the full year [11][12] - Cash position is expected to improve by approximately €80 million in 2025, excluding any potential acquisitions [10]

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--If approved, Lenivia will be a new antibody therapy that reduces OA pain in dogs for three months with one injection. ...

Key Takeaways NEOG's first-quarter EPS missed by 20% as revenues came in above consensus at $209.2 million.Neogen's Q1 Food Safety fell 4.6%, Animal Safety down 0.8%, Genomics returned to mid-single-digit growth.Neogen expects fiscal 2026 revenues of $820-$840M, adjusted EBITDA $165-$175M and CapEx of around $50M.Neogen Corporation (NEOG) reported first-quarter fiscal 2026 adjusted earnings per share (EPS) of 4 cents, which missed the Zacks Consensus Estimate by 20%. The bottom line fell 42.9% from the year ...

PORTLAND, Maine, Oct. 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2025. Since the first quarter of 2020, the Company has been providing a preliminary look at its unaudited top line results soon afte ...

Core Insights - Three stocks are highlighted with a buy rank and strong income characteristics for investors to consider on October 7th [1] Group 1: MGIC Investment Corporation (MTG) - MGIC Investment Corporation is a mortgage insurance company with a Zacks Rank 1 [1] - The Zacks Consensus Estimate for its current year earnings has increased by 10.1% over the last 60 days [1] - The company offers a dividend yield of 3.2%, significantly higher than the industry average of 0.0% [1] Group 2: Phibro Animal Health Corporation (PAHC) - Phibro Animal Health Corporation operates in animal health and mineral nutrition with a Zacks Rank 1 [2] - The Zacks Consensus Estimate for its current year earnings has risen by 10% over the last 60 days [2] - The company has a dividend yield of 1.3%, compared to the industry average of 0.0% [2] Group 3: International Consolidated Airlines Group S.A. (ICAGY) - International Consolidated Airlines Group S.A. provides passenger and cargo transportation services and holds a Zacks Rank 1 [3] - The Zacks Consensus Estimate for its current year earnings has increased by 11.8% over the last 60 days [3] - The company has a dividend yield of 1.1%, which is lower than the industry average of 2.8% [3]

Core Insights - Three stocks are highlighted with a buy rank and strong value characteristics for investors to consider on October 6th [1][2][3] Group 1: Elanco Animal Health Incorporated (ELAN) - Elanco has a Zacks Rank 1 and a 4.8% increase in the Zacks Consensus Estimate for current year earnings over the last 60 days [1] - The company has a price-to-earnings ratio (P/E) of 23.42, compared to 24.73 for the S&P 500 [1] - Elanco possesses a Value Score of B [1] Group 2: HF Sinclair Corporation (DINO) - HF Sinclair also carries a Zacks Rank 1, with a 24.8% increase in the Zacks Consensus Estimate for current year earnings over the last 60 days [2] - The company has a price-to-earnings ratio (P/E) of 14.46, significantly lower than the S&P 500's 24.73 [2] - HF Sinclair has a Value Score of B [2] Group 3: Embecta Corp. (EMBC) - Embecta holds a Zacks Rank 1, with a 4.3% increase in the Zacks Consensus Estimate for current year earnings over the last 60 days [3] - The company has a price-to-earnings ratio (P/E) of 4.89, which is much lower than the S&P 500's 24.73 [3] - Embecta possesses a Value Score of A [3]

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the French Financial Market Authority – Autoritédes Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rightsSeptember, 30 20258 390 660Gross total of voting rights : 12 705 441Net total* of voting rig ...

Core Insights - IDEXX Laboratories, Inc. is recognized as one of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years, specializing in animal health diagnostics and related services [1] - The company reported Q2 earnings for August 2025, with revenue of $1.11 billion, marking a 10.6% year-over-year increase, and earnings per share of $3.63, exceeding market expectations [2] - The launch of the inVue Dx analyzer has been a significant growth driver, with 2,400 units installed in Q2, leading to an upward revision of the full-year installation target to 5,500 units [3] - IDEXX shares have delivered a 97% return over the past three years, outperforming competitors like Zoetis and the broader market, with projected earnings per share for 2025 between $12.40 and $12.76 [4]

We recently compiled a list of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years. Zoetis Inc. is one of them. Zoetis Inc. (NYSE:ZTS), a global leader in animal health, reported solid second-quarter 2025 results with revenue rising 4% year-over-year to $2.5 billion and net income up 15% to $718 million. Growth was driven by an 8% increase in companion animal product sales, led by flagship products such as Simparica Trio for parasite prevention and pain and dermatology treatments, including Rela Sol ...